Skip to main content

Table 2 Biologically corrected EQD2 dose with the inclusion of uniform 45 Gy from external beam radiotherapy prior to the SFRT boost. Comparator data derives from brachytherapy treatments while the last column reports the data from the SBRT study of Albuquerque et al. [5]. The ranges are reported in square brackets

From: A novel external beam radiotherapy method for cervical cancer patients using virtual straight or bending boost areas; an in-silico feasibility study

Structure

Param

Obj

SFRT_1

SFRT_2

SBRT

Comparator

Albuquerque

CTV

D90%

84.25 Gy

84.25

84.25

84.25

88.2 ± 1.8

 

V45Gy (150%)

≥ 50–55%

43.1 ± 7.5

[33.0,55.9]

56.6 ± 5.6

[45.4,64.8]

2.3 ± 3.8

[0,10.6]

61.0 ± 3.8

[56.0,66.4]

 

V60Gy (200%)

≥ 30%

15.4 ± 5.6

[6.9,23.9]

26.8 ± 6.6

[17.3,34.2]

0

[0,0]

37.2 ± 3.6

[31.6,41.8]

PTV2mm

D90%

84.25 GY

72.6 ± 2.2

[69.2,74.7]

72.9 ± 2.2

[72.1,75.3]

72.4 ± 2.1

[69.9,74.4]

PTV5mm

D90%

84.25 Gy

67.6 ± 2.1

[64.5,70.3]

68.2 ± 2.5

[63.8,71.0]

67.4 ± 2.1

[64.2,69.3]

Bladder

D2cm3

≤ 80.0 Gy

76.6 ± 4.9

[71.7,88.5]

76.9 ± 5.2

[72.6,89.3]

75.0 ± 5.5

[66.7,86.4]

66.5 ± 5.9

[56.8,86.9]

99.6 (*)

Rectum

D2cm3

≤ 65.0 Gy

59.5 ± 5.5

[53.5,72.6]

58.0 ± 5.0

[53.7,68.4]

57.8 ± 7.2

[50.6,74.9]

53.1 ± 4.1

[48.0,58.9]

90.6 (*)

Sigmoid

D2cm3

≤ 70.0 Gy

45.4 ± 3.2

[44.0,53.7]

45.4 ± 3.1

[43.5,53.1]

45.2 ± 2.5

[43.4,50.6]

61.5 ± 2.7

[57.0,66.2]

80.7 (*)

Bowel

D2cm3

≤ 65.0 Gy

52.8 ± 7.7

[43.9,66.1]

52.9 ± 8.4

[45.0,67.8]

54.1 ± 9.1

[45.1,67.0]

54.3 ± 7.1

[46.3,67.3]

67.9 (*)

  1. Dx: dose received by at least X% or Xcm3 of the volume, SFRT: spatially fractionated radiation therapy, SBRT: stereotactic body radiation therapy, CTV: clinical target volume, PTV: planning target volume, (*) median values